Loading company…
Seraphina Therapeutics develops consumer health products centered on fatty acids, led by its C15:0 product for nutrient replenishment.
Founded in 2017 and headquartered in San Diego, US, Seraphina Therapeutics was co-founded by Eric Venn-Watson and Stephanie Venn-Watson, who also serves as CEO. Its flagship product, C15:0 (pentadecanoic acid), is marketed to health-conscious consumers and aging populations in North America and Europe through direct sales and retail partners. In October 2021 the company raised USD 5 mn in Series A funding, with participation from Cue Ball Capital and Domain Associates.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in